Receptor occupancy (RO) correlates the dose of drug administered to the percentage of receptors occupied by the drug compound, which helps decide dosing of drug candidates entering clinical trials, and tailor drug dosage for individualized therapies. However, in vivo measurement of RO in solid tumor is hindered by both tissue properties and technical limitations. Here we present the progress of developing a near-infrared, paired-agent imaging (PAI) approach for real-time measurement of anti-tumor drug RO in vivo. In this study, xenograft murine model with orthotopic tumor implant was imaged using a pair of imaging agent: ABY-029, an affibody-dye conjugate, targeting epidermal growth factor receptor (EGFR), together with IRDye 680LT, a pharmacokinetically similar probe devoid of EGFR specificity. Concentration of tumor EGFR free of drug binding was quantified by binding potential (BP), a parameter calculated from fluorescence signals of the agent pair. We demonstrated that BP was decreased by subsequent administration of drug homolog, indicating drug-EGFR engagement in the tumor. The results demonstrated the ability of PAI to reflect displacement of EGFR-bound ABY-029 by anti-EGFR drug molecules, and the potential to be applied for in vivo RO measurement.
|